injection-site erythema, injection-site extravasation, injection-site haematoma, injection-site induration, injection-site mass, injection-site nodule, injection-site pain, injection-site pruritus, injection-site reaction, and injection-site swelling. †Diarrhoea (n=1), maternal exposure during pregnancy (n=1), breast cancer (n=1), injection-site reaction (n=4), myocardial infarction (n=1), nausea (n=4), cerebrovascular accident (n=1), gastritis (n=1), leukaemia (n=1), oedematous pancreatitis (n=1), myalgia (n=1), headache (n=1), vomiting (n=1), lip swelling (n=1), non-Hodgkin lymphoma (n=1), and lethargy (n=1). ‡Nausea (n=1), colon cancer (n=1), hypoaesthesia oral (n=1), oesophageal carcinoma (n=1), and Cushing’s syndrome (n=1).  Table 3: Overview of treatment-related adverse events Figure 4: Exposure-adjusted rates of overall hypoglycaemia